• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Personalizing Lung Cancer Management With ctDNA: Where We Are and Where We Are Headed

by MM360 Staff | Apr 16, 2025 | Uncategorized

Source: ASCO Daily News Dr. Vamsi Velcheti and Dr. Charu Aggarwal discuss the evolution of ctDNA as a critical tool in precision oncology and its implications for lung cancer management, including its potential role in the early-stage setting. TRANSCRIPT Dr. Vamsi...

Clinical Trial of NEO100 Recruiting Patients With Malignant Gliomas

by MM360 Staff | Apr 16, 2025 | Uncategorized

Source: CureToday articles A phase 2a clinical trial of NEO100-01 is continuing to recruit patients with malignant gliomas, with full enrollment expected in September. Read More

First Patient Treated in Trial of PHST001 for Advanced Solid Tumors

by MM360 Staff | Apr 16, 2025 | Uncategorized

Source: CureToday articles Pheast Therapeutics has treated the first patient in a phase 1 trial of PHST001, a novel macrophage checkpoint inhibitor for advanced solid tumors. Read More

Spring Looks Different This Year

by MM360 Staff | Apr 16, 2025 | Uncategorized

Source: CureToday articles What is lovely never dies, but passes into other loveliness, Stardust or seafoam, flower or winged air. ― Thomas Bailey Aldrich Read More

Subcutaneous Opdivo Similarly Effective, Safe as IV for Advanced ccRCC

by MM360 Staff | Apr 16, 2025 | Uncategorized

Source: CureToday articles Subcutaneous Opdivo showed comparable effectiveness, safety and tolerability to IV Opdivo in advanced clear cell renal cell carcinoma. Read More

Understanding How to Advance Immunotherapy Strategy Models in Melanoma

by MM360 Staff | Apr 16, 2025 | Uncategorized

Source: CureToday articles Melanoma is a key cancer type for developing and testing immunotherapies prior to broader clinical application across other malignancies. Read More
« Older Entries
Next Entries »

Recent Content

  • EHA–EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma
  • Patient-reported physical function has ‘real clinical value’ for treating multiple myeloma
  • Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma
  • The impact of high-risk cytogenetics on treatment efficacy and outcomes of patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis of randomized controlled trials
  • FDA Approves Linvoseltamab-Gcpt for Treatment of Relapsed or Refractory Multiple Myeloma
  • FDA Grants Accelerated Approval to Lynozyfic for Multiple Myeloma
  • FDA accelerates linvoseltamab-gcpt approval for multiple myeloma
  • Comprehensive machine learning analysis of PANoptosis signatures in multiple myeloma identifies prognostic and immunotherapy biomarkers
  • The impact of high-risk cytogenetics on treatment efficacy and outcomes of patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis of randomized controlled trials
  • Spatial and single cell mapping of castleman disease reveals key stromal cell types and cytokine pathways
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT